NANOBIOTIX Announces Closing of Global Offering

Nanobiotix, a late-clinical stage biotechnology company, announced the closing of its global offering on May 26, 2026, raising approximately $100 million in gross proceeds following the full exercise of underwriters' over-allotment option. The company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants at €33.60 per share. Net proceeds will be allocated toward advancing the Nanoprimer platform (50-60%), general corporate purposes (30-40%), and JNJ-1900 development (less than 10%). The company expects its financial resources to support operations into 2029.